株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

加齢黄斑変性症 (AMD) およびその他の網膜疾患:世界の治療薬市場 2017-2027年

Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Age-Related Macular Degeneration, Dry AMD, Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion & Geographic Atrophy

発行 Visiongain Ltd 商品コード 290418
出版日 ページ情報 英文 196 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=155.00円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
加齢黄斑変性症 (AMD) およびその他の網膜疾患:世界の治療薬市場 2017-2027年 Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Age-Related Macular Degeneration, Dry AMD, Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion & Geographic Atrophy
出版日: 2017年07月17日 ページ情報: 英文 196 Pages
概要

世界の網膜疾患治療薬市場規模は、2017年に119億8,000万米ドルに達すると予測されています。同市場は2017年から2027年にかけて力強い収益拡大を達成する見込みです。

当レポートでは、加齢黄斑変性症 (AMD) をはじめとした網膜疾患のための薬剤市場について調査し、売上動向、技術動向、市場の機会とともに収益予測、2次市場 (ウェット型AMD・ドライ型AMD・DR (糖尿病網膜症) ) の動向などをまとめて取り上げております。

第1章 調査概要

第2章 世界の加齢黄斑変性症 (AMD) およびその他の網膜疾患市場

  • 網膜疾患とは
  • 網膜疾患の種類
  • AMDおよびその他の網膜疾患診断・治療
  • 約2億人がAMDを患う?
  • 1億人以上がDR (糖尿病網膜症) を患う
  • 最初のRVO (網膜静脈閉塞症) 推計は1,600万人の患者人口を示唆
  • 2027年まで急速に発展する市場
  • Eylea (アイリーア) は市場をリードする治療薬
  • Regeneron社は市場プレゼンスが高い
  • 市場で最も大きな疾病領域は?

第3章 網膜疾患市場の2次市場

  • ウェット型AMDは依然として市場の主要な収益源
  • ウェット型AMD:血管由来のプロセスが明確に定義された薬剤標的を提供
  • ドライ型AMD:網膜色素上皮 (RPE) 細胞へのダメージを阻止または無効にするためのアンメットニーズ
  • DR (糖尿病網膜症) :糖尿病黄斑浮腫 (DME) をターゲットとして、臨床的な関心事となる
  • Lucentis ・ Eylea の延長試験はその他の新刊領域における可能性を明らかに
  • 全セグメントの予測

第4章 加齢黄斑変性症 (AMD) およびその他の網膜疾患市場における承認済み製品

  • 現在の製品が2027年まで市場を独占するか
  • Lucentis:市場で第2位の治療薬
  • Eylea:首位に立っているか?
  • Avastin:正式な承認がないが最もよく使われる製品
  • Visudyne (Valeant/Novartis): 調査対象期間中は売上が減少する見込み
  • Jetrea (ThromboGenics/Novartis): 2013年の発売は期待外れ

第5章 ウェット型AMDセグメントのパイプライン

  • 主なパイプライン候補薬
  • Fovista (Ophthotech Corporation/Novartis) :次の目玉?
  • パイプラインにおけるターゲットのその他の成長因子
  • Conbercept (Chengdu Kanghong Biotech): ウェット型AMD治療薬として中国で発売
  • 新規の抗VEGFR剤またはデリバリーシステムを必要としているか?
  • 抗炎症アプローチを活性化させるための新デリバリーシステム
  • ウェット型AMD薬剤開発で研究中のその他のターゲット
  • 再生医療アプローチ

第6章 ドライ型AMDセグメントのパイプライン

  • ドライ型AMDにおいて大躍進を遂げるのはどれか?
  • MC-1101 (MacuCLEAR)
  • ACU-4429 (Acucela) :第?相試験における視覚サイクルモデュレーター
  • ドライ型AMDにおける補体阻害への大きな期待
  • 副腎皮質ステロイド (コルチコステロイド) :ドライ型AMDの発症における炎症の役割をターゲットに
  • 神経防護作用:現代医療の至高の目標の一つ
  • 再生医療:ドライ型AMDは最大の疾病ターゲットの一つ
  • ドライ型AMDのその他の治療法

第7章 糖尿病性網膜症 (DR) セグメントのパイプライン

  • Ozurdex/Posurdex (Allergan) :一般的なDME患者のための認可
  • Lucentis (ルセンティス) :DRのゲームチェンジャー?
  • 新たな抗VEGFの追加
  • DR向けに開発中のステロイド
  • DR向けに開発中のその他の製品

第8章 地域市場の分析

  • 最も収益拡大の可能性のある市場とは
  • 米国:網膜疾患の大手市場
  • 日本:安定した市場の可能性
  • 欧州5か国:高齢化が市場成長を牽引
  • BRIC諸国:市場の最大成長牽引者

第9章 産業・市場の定性的分析

  • 強み
  • 弱み
  • 機会
  • 脅威
  • 社会的
  • 技術的
  • 経済的
  • 政治的

第10章 結論

  • Lucentisの老朽化:終焉が近付きつつあるか?
  • Lucentis vs. Eyla vs. Avastin:抗VEGF市場の3つの方向性
  • ウェット型以外での症状が重要性を増す
  • ドライ型市場が大きな可能性をもつ
  • Fovistaがパイプライン候補の中で最も有望
  • 網膜疾患が眼病の主要分野であり続ける

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0213

Title:
Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027
Outlook & Analysis for Ophthalmic Drugs for Other Retinal Diseases Including Age-Related Macular Degeneration (ARMD), Dry AMD, Wet AMD, Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) & Geographic Atrophy (GA).

Macular Degeneration, Diabetic Retinopathy and Other Retinal Diseases - our new study reveals trends, R&D progress, and predicted revenues

Where is the Retinal disease therapeutic market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 169-page report provides 80 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Retinal Disease market. See how to exploit the opportunities.

Forecasts from 2017-2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you find revenue forecasts to 2027 for the following submarkets:

  • Wet age-related macular degeneration (wAMD)
  • Dry AMD (dAMD)
  • Diabetic retinopathy (DR)
  • Other retinal diseases (grouped forecast).

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products' sales - what's possible for those eye drug revenues?

How will individual retinal medicines perform from 2017 to 2027 at world level? Our study forecasts revenues of four prominent brands:

  • Lucentis
  • Eylea
  • Avastin
  • Visudyne

Discover how high revenues can go. See what's happening, understanding the trends, challenges and opportunities.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?

You will discover individual revenue forecasts for 10 leading national markets from 2017-2027:

  • United States (US)
  • Japan
  • Germany, France, the UK, Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).

Leading companies and the potential for market growth

Our analysis forecasts that the world market for retinal drugs will reach $11.98bn in 2017. It will achieve strong revenue expansion from 2017 to 2027. Our report reveals how high sales will go over the next 10 years.

Research and development - assess innovation, trends and possibilities

There you can also investigate R&D, appraising technological, clinical and commercial possibilities.

In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others:

  • Combination therapies, including neovascularisation disrupters
  • Angiogenesis inhibition by blocking pericyte recruitment
  • Anti-inflammatory mechanisms (inc. corticosteroids)
  • Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
  • Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore the other agents and possibilities, too, including these:

  • Oligonucleotides and siRNA therapy
  • Anti-integrin oligopeptide treatment
  • Complement factor inhibition and serotonin modifiers
  • Angiotensin receptor blockers and converting enzyme inhibitors
  • Biosimilars and other follow-on biologicals and next generation therapeutics
  • Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Get our report today Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Other Retinal Diseases Including Age-Related Macular Degeneration (ARMD), Dry AMD, Wet AMD, Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) & Geographic Atrophy (GA). Avoid missing out - get our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Why You Should Read This Report
  • 1.2. How This Report Delivers
  • 1.3. Main Questions Answered by This Analysis
  • 1.4. Who Is This Study For?
  • 1.5. Methods of Research and Analysis
  • 1.6. Frequently Asked Questions (FAQs)
  • 1.7. Some Associated Reports
  • 1.8. About Visiongain

2. World AMD and Other Disease Market, 2016

  • 2.1. What are Retinal Diseases?
  • 2.2. Types of Retinal Diseases
  • 2.3. Diagnostics and Treatments for AMD and Other Retinal Diseases
  • 2.4. Nearly 200 Million People with AMD?
  • 2.5. Over 100 Million with DR
  • 2.6. First RVO Estimates Suggest Patient Population of 16 Million
  • 2.7. Market to Make Rapid Pace to 2027
  • 2.8. Eylea Stood as the Leading Drug in the Market
  • 2.9. Regeneron the Leading Presence in the Market
  • 2.10. Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2016

  • 3.1. Wet AMD Still the Main Source of Revenue in the Market
  • 3.2. Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
    • 3.2.1. Revenue Forecasting for Wet AMD segment, 2016-2027
  • 3.3. Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
    • 3.3.1. Dry AMD Segment to Emerge in the Forecast Period
  • 3.4. DR: Coming Into Clinical Focus, with DME the Main Target
    • 3.4.1. Segment to Grow in Importance as Diabetes Epidemic Continues
  • 3.5. Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
  • 3.6. Projections for All Segments, 2016-2027

4. Approved Products in the AMD and Other Retinal Diseases Market, 2016-2027

  • 4.1. Will the Current Products Dominate the Market Through 2027?
  • 4.2. Lucentis: Second Leading Drug in the Market
    • 4.2.1. Positive Revenue Growth Shown in Past: 2012-2016
    • 4.2.2. Shadow of Avastin Still Hangs Over Lucentis
    • 4.2.3. CATT Study Results: Clinical Differences Still Have Yet to Emerge
    • 4.2.4. Eylea: The Bigger Threat to Lucentis?
    • 4.2.5. Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
    • 4.2.6. Improving Cost and Compliance for Lucentis
    • 4.2.7. Lucentis Revenue Forecast 2016-2027
    • 4.2.8. Will Loss of Physician Goodwill Harm Lucentis' Growth?
  • 4.3. Eylea: Holds the Throne?
    • 4.3.1. Increasing Revenue Growth in Past: Outside US Sale Amplified
    • 4.3.2. VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
    • 4.3.3. First Wave of Eylea's Expansion Finally Beginning to Break?
    • 4.3.4. Eylea into DME and Other New Indications
    • 4.3.5. Eylea Revenue Forecast 2016-2027
    • 4.3.6. How Far Can Eylea's Momentum Carry It?
  • 4.4. Avastin: No Formal wAMD Approval but Still the Most-Used Product
    • 4.4.1. Past Revenue illustrates Increasing Use of Avastin for wetAMD
    • 4.4.2. Judicial Review Averted in the UK by Price Adjustment
    • 4.4.3. Multiple Attempts to Block Off-Label Avastin Since 2007
    • 4.4.4. Roche and Novartis Challenge CATT's Headline Conclusions
    • 4.4.5. Will Eylea/Zaltrap Affect Avastin's Place in the Market?
    • 4.4.6. Avastin Revenue Forecast, 2016-2027
    • 4.4.7. Will Anything Dislodge Avastin from its Central Position?
  • 4.5. Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
    • 4.5.1. Visudyne Revenue Forecast, 2016-2027
  • 4.6. Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013

5. Pipeline for Wet AMD Segment, 2016-2027

  • 5.1. The Leading Pipeline Candidates
  • 5.2. Fovista (Ophthotech Corporation/ Novartis): The Next Big Thing?
    • 5.2.1. Three Phase 3 Trials to Confirm Fovista's Outstanding Phase 2 Results
    • 5.2.2. Ophthotech Goes Public to Fund Phase 3 Effort
    • 5.2.3. Ophthotech Partners with Novartis for Fovista
    • 5.2.4. Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
    • 5.2.5. The Move toward Combination Therapies
    • 5.2.6. Biosmiliars of Lucentis: FYB201 & PF-582
    • 5.2.7. TK001/sevacizumab (Jiangsu T-Mab Biopharma)‘s recombinant humanized anti-VEGF monoclonal antibody
    • 5.2.8. Roche's RG7716 (RO-6867461), an anti- VEGF A monoclonal antibody
    • 5.2.9. Opthea's OPT-302, a VEGFR inhibitor
    • 5.2.10. Daiichi Sankyo's DS7080, an angiogenesis inhibitor
  • 5.3. Other Growth Factor Targets in the Pipeline
    • 5.3.1. Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
    • 5.3.2. Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
    • 5.3.3. NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
    • 5.3.4. Regeneron's REGN910-3 (Nesvacumab + Aflibercept) and REGN910 (Nesvacumab)
    • 5.3.5. iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
  • 5.4. Conbercept (Chengdu Kanghong Biotech): Launched in China for wAMD
    • 5.4.1. A Chinese Competitor: Where Will Conbercept Fit In?
    • 5.4.2. Binding Affinity Comparable to Eylea
  • 5.5. Do We Need New Anti-VEGFR Agents or Delivery Systems?
    • 5.5.1. Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
    • 5.5.2. Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
    • 5.5.3. PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
    • 5.5.4. NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
    • 5.5.5. Pan-90806 (PanOptica): Anti-VEGF Eyedrop
    • 5.5.6. Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
  • 5.6. Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
    • 5.6.1. Verisome System and IBI-30089 (Icon Bioscience)
  • 5.7. Other Targets Under Investigation in wAMD Drug Development
    • 5.7.1. Are Kinase Inhibitors Still a Going Concern in wAMD?
    • 5.7.2. Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
    • 5.7.3. X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
    • 5.7.4. Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
    • 5.7.5. Integrins: Another Blockable Component of the Neovascularisation Cascade?
    • 5.7.6. Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
    • 5.7.7. SF0166 (SciFluor Life Sciences): an integrin αvβ3 inhibitor for Wet AMD
    • 5.7.7. Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
    • 5.7.8. Novel Anti-Angiogenic Treatments in Development: Ora Bio's ORA102 and CoMentis' ATG003
    • 5.7.9. Zybrestat (Mateon Therapeutics Oxigene, formerly OxiGENE): New Mechanism of Action Offers Way to Disrupt Neovascularisation
    • 5.7.10. Alcon's LMG324 and LHA510 for wAMD
    • 5.7.11. hI-con1 (Iconic Therapeutics), VII-IgGFc chimeric protein targeting tissue factor
    • 5.7.12. Synthetic Biologics: Oligonucleotides and SiRNAs for wAMD
  • 5.8. Regenerative Medicine Approaches
    • 5.8.1. Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
    • 5.8.2. AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
    • 5.8.3. RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
    • 5.8.5. Gene Therapy (RGX-314) for Neovascular AMD
    • 5.8.6. Stem cell therapy with Pfizer's PF05206388
    • 5.8.7. Diffusion Pharmaceuticals' Palomid-529
    • 5.8.8. MT-0814 (Mitsubishi Tanabe Pharma), CC chemokine receptor 3 antagonist for AMD
    • 5.8.9. Undisclosed MoA of Boehringer Ingelheim's BI 144807 for Wet AMD

6. Pipeline for Dry AMD Segment, 2016

  • 6.1. Who Will Achieve the Big Breakthrough in Dry AMD?
  • 6.2. MC-1101 (MacuCLEAR): Leading the Pack?
    • 6.2.1. Increasing Choroidal Blood Flow with Repurposed Product
    • 6.2.2. Novel Endpoints in Phase 3 Study
    • 6.2.3. Can MacuCLEAR Make It?
  • 6.3. ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
    • 6.3.1. Disappointing results of Phase 2/3 trial
  • 6.4. High Hopes for Complement Inhibition in Dry AMD
    • 6.4.1. Lampalizumab (Roche): The Big News of ARVO 2013
    • 6.4.2. MAHALO Study Indicates GA Progression Slowed by Lampalizumab
  • 6.5. Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
    • 6.5.1. Iluvien (Alimera Sciences): Study terminated
    • 6.5.2. AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
  • 6.6. Neuroprotection: One of Modern Medicine's Holy Grails
    • 6.6.1. Tandospirone (Alcon): Not effective in GA
    • 6.6.2. Neurotech's Renexsus: Possibly Promising Data in Dry AMD Studies
    • 6.6.3. Novadur (Allergan): Possible Efficacy with Longer Duration of Action
  • 6.7. Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
    • 6.7.1. MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
    • 6.7.2. HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
    • 6.7.3. Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
    • 6.7.4. OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
    • 6.7.5. First iPSC Trial in Japan in Dry AMD Patients
    • 6.7.6. Ophthotech's Zimura for Geographic Atrophy
    • 6.7.7. Gene Therapies Less Prominent Than Stem Cells in Dry AMD
  • 6.8. Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment, 2016

  • 7.1. Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
  • 7.2. Lucentis: The Game Changer for DR?
  • 7.3. New Anti-VEGF Additions
    • 7.3.1. Is Eylea Better than Lucentis and Avastin for DME?
  • 7.4. Steroids in Development for DR
    • 7.4.1. Iluvien (Alimera/pSivida): New Option in European Markets
    • 7.4.2. A New Hope? Optina (Ampio Pharmaceuticals)
    • 7.4.3. Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
    • 7.4.4. Clearside Biomedical's CLS-TA/ CLS1004
    • 7.4.5. IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
    • 7.4.6. Kala Pharmaceuticals' KPI-121
  • 7.5. Other Products in Development for DR
    • 7.5.1. Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
    • 7.5.2. Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
    • 7.5.3. TriLipix (Abbott): No New Development for Promising Drug
    • 7.5.4. Jetrea (ThromboGenics /Novartis): Possibilities in DME?
    • 7.5.5. SF0166 (SciFluor Life Sciences): an integrin αvβ3 inhibitor for DME
    • 7.5.6. Pan-90806 (PanOptica): Anti-VEGF Eyedrop
    • 7.5.7. Teprotumumab (Horizon Pharma): an insulin-like growth factor-1 receptor antagonist
  • 7.6. Undisclosed MoA of Boehringer Ingelheim's BI 1026706 for DME

8. Regional Market Breakdown, 2016

  • 8.1. Which Markets Hold the Most Revenue Growth Potential?
  • 8.2. The US: Leading Market for Retinal Diseases
  • 8.3. Japan: Strong Market Potential
  • 8.4. EU5: Ageing Populations to Drive Market Growth
  • 8.5. BRIC Nations: The Biggest Growth Driver for the Market

9. Qualitative Industry and Market Analysis, 2017-2027

  • 9.1. Strengths: The Most Dynamic Area of the Ophthalmics Market
  • 9.2. Weaknesses: Heavily Dependent on Anti-VEGF Approach
  • 9.3. Opportunities: New Markets and R&D Synergies
  • 9.4. Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
  • 9.5. Social: Low Diagnosis, Low Compliance
  • 9.6. Technological: Innovation for the Eye
  • 9.7. Economic: Off-Label Treatment and Reimbursement Issues
  • 9.8. Political: The Demography and Diabetes Challenges

10. Report Conclusions

  • 10.1. The Age of Lucentis: Nearing Its Conclusion?
  • 10.2. Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
  • 10.3. Indications Outside Wet AMD to Gain in Importance
  • 10.4. Dry AMD Market Has Huge Potential
  • 10.5. Fovista Most Prominent Among the Pipeline Candidates
  • 10.6. Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
  • Associated Visiongain Reports
  • Glossary
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Figures

  • Figure 2.1: Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2016-2027
  • Figure 2.2: Market Breakdown by Product Revenue ($bn), Market Share (%), 2016
  • Figure 2.3: Market Breakdown by Company: Market Share (%), 2016
  • Figure 2.4: Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
  • Figure 2.5: Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
  • Figure 3.1: Market Breakdown by Disease Segment: Revenues ($bn), 2016
  • Figure 3.2: Market Breakdown by Disease Segment: Market Share (%), 2016
  • Figure 3.3: Wet AMD Segment Forecast: Revenue ($bn), 2016-2027
  • Figure 3.4: Dry AMD Segment Forecast: Revenue ($bn), 2016-2027
  • Figure 3.5: DR Segment Forecast: Revenue ($bn), 2016-2027
  • Figure 3.6: Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2016-2027
  • Figure 3.7: Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2016, 2021 and 2027
  • Figure 3.8: Market Breakdown by Disease Segment: Market Share (%), 2021
  • Figure 3.9: Market Breakdown by Disease Segment: Market Share (%), 2027
  • Figure 4.1: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2021
  • Figure 4.2: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2027
  • Figure 4.3: Market Forecast by Product: Revenue ($bn), 2016-2027
  • Figure 4.4: Market Breakdown by Product: Revenue ($bn), 2016, 2021 and 2027
  • Figure 4.5: Lucentis: Revenues Forecast ($bn), 2016-2027
  • Figure 4.6: Drivers and Restraints for Lucentis, 2016
  • Figure 4.7: Eylea Forecast: Revenue ($bn), 2016-2027
  • Figure 4.8: Drivers and Restraints for Eylea, 2016
  • Figure 4.9: Avastin Forecast: Revenue ($bn), 2016-2027
  • Figure 4.10: Drivers and Restraints for Avastin, 2016
  • Figure 4.11: Visudyne Forecast: Revenues ($bn), 2016-2027
  • Figure 8.1: Regional Breakdown: Revenue ($bn), 2016-2027
  • Figure 8.2: Regional Breakdown: Revenue ($bn), 2016, 2021 and 2027
  • Figure 8.3: Regional Market Share (%), 2016
  • Figure 8.4: Regional Market Share (%), 2021
  • Figure 8.5: Regional Market Share (%), 2027
  • Figure 8.6: US Market: Revenue ($bn), 2016-2027
  • Figure 8.7: Japan: Revenue ($bn), 2016-2027
  • Figure 8.8: EU5: Grouped Revenue ($bn), 2016-2027
  • Figure 8.9: EU5 Breakdown Forecasts: Revenue ($bn), 2016-2027
  • Figure 8.10: EU5 Breakdown: Market Share (%), 2016
  • Figure 8.11: EU5 Breakdown: Market Share (%), 2021
  • Figure 8.12: EU5 Breakdown: Market Share (%), 2027
  • Figure 8.13: BRIC Nations Forecast: Grouped Revenue ($bn), 2016-2027
  • Figure 8.14: BRIC Nations Forecasts: Revenue ($bn), 2016-2027
  • Figure 8.15: Market Share (%) within BRIC Group by Country, 2016
  • Figure 8.16: Market Share (%) within BRIC Group by Country, 2021
  • Figure 8.17: Market Share (%) within BRIC Group by Country, 2027

List of Tables

  • Table 1.1: Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 1.2: Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 2.1: Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 2.2: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2016
  • Table 3.1: Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2016
  • Table 3.2: Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2016
  • Table 3.3: Wet AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2027
  • Table 3.4: Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2027
  • Table 3.5: DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2027
  • Table 3.6: Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 3.7: Retinal Diseases Market Forecasts by Segment: Revenue ($bn), Market Share (%) for 2016, 2021 and 2027
  • Table 4.1: Major Retinal Drugs Market Forecast: Revenue ($bn), CAGR (%) for 2016-2027
  • Table 4.10: Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.3: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2027
  • Table 4.4: Lucentis: Revenue ($bn), AGR (%), 2012-2016
  • Table 4.5: Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
  • Table 4.6: Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.7: Eylea: Revenue ($bn), AGR (%), 2013-2016
  • Table 4.8: Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.9: Avastin: Revenue ($bn), AGR (%), 2012-2014
  • Table 4.11: Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.2: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2021
  • Table 5.1: Selected R&D Pipeline (Phase 3) for wAMD, 2016
  • Table 5.2: Selected R&D Pipeline (Phase 2 & 1/2) for wAMD, 2016
  • Table 5.3: Selected R&D Pipeline (Phase 1) for wAMD, 2016
  • Table 6.1: Selected R&D Pipeline (Phase 2 & 3) for Dry AMD, 2016
  • Table 6.2: Selected R&D Pipeline (Phase 2 & 3) for Dry AMD, 2016
  • Table 7.1: Selected R&D Pipeline (Phase 2 & 3) for Diabetic Retinopathy, 2016
  • Table 7.2: Selected R&D Pipeline (Phase 1 & !/2) for Diabetic Retinopathy, 2016
  • Table 8.1: Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 8.1: Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2016-2027 (continued)
  • Table 8.2: US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 8.3: Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 8.4: EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 8.5: BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 9.1: Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2016
  • Table 9.2: Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2016
  • Table 9.3: Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2016-2027

Companies Listed

  • Abbott
  • Acucela
  • AgeX Therapeutics
  • Alcon
  • Alimera Sciences
  • Allegro Opthalmics
  • Allergan
  • Ampio Pharmaceuticals
  • Avalanche Biotechnologies
  • Bayer Healthcare
  • Bioeq GmbH
  • Biophytis
  • Biovail Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CalTech
  • Cell Cure Neurosciences Ltd
  • Centocor
  • Chengdu Kanghong Biotech
  • Clearside Biomedical
  • CoMentis
  • Daiichi Sankyo
  • Diffusion Pharmaceuticals
  • Eli Lilly
  • ESBATech
  • Eye Gate Pharmaceuticals
  • ForSight Vision4
  • Gene Signal
  • Genentech
  • GlaxoSmithKline
  • Hemera Biosciences
  • Icon Bioscience
  • Iconic Therapeutics
  • Janssen Pharmaceuticals
  • Jiangsu T-mab BioPharma
  • Kala Pharmaceuticals
  • LPATH
  • MacuCLEAR
  • Mateon Therapeutics
  • Medical Need
  • Merck Sharp & Dohme
  • Mesoblast
  • Mitsubishi Tanabe Pharma
  • Molecular Partners
  • MorphoSys
  • Neuron Systems
  • Neurotech
  • Novartis
  • Novo Nordisk
  • Oakwood Laboratories
  • Ocata Therapeutics (Advanced Cell Technology)
  • OHR Pharmaceutical
  • Ophthotech Corporation
  • OpRegen (Biotime)
  • Opthea
  • Othera Pharmaceuticals
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • Oxigene
  • PanOptica
  • Pfenex
  • Pfizer
  • pSivida
  • Quark
  • Regenerative Patch Technologies
  • Regeneron/Bayer
  • Regenxbio
  • River Vision Development
  • Roche
  • RXi Pharmaceuticals
  • Sanofi
  • Santen Pharmaceutical
  • SciFluor Life Sciences
  • Senju Pharmaceutical
  • SGS Life Science Services
  • Stealth BioTherapeutics
  • StemCells
  • Stemedica Cell Technologies
  • SV Life Sciences
  • Third Rock Ventures
  • ThromboGenics
  • Tyrogenex
  • UCB
  • Valeant Pharmaceuticals
  • Xcovery Vision

List of Organisations

  • Association for Research in Vision and Ophthalmology
  • Columbia University
  • Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • International Diabetes Federation
  • Italian Competition Authority (ICA)
  • Japanese Ministry of Health, Labour and Welfare
  • NHS
  • NICE
  • Oregon Health and Science University
  • UK's General Medical Council
  • University College London (UCL)
  • US National Eye Institute
  • WHO
Back to Top